Drugs/Recall·openFDA/drug

Guardian Drug Co. Inc. — Class II: HyVee, Ultra Strength Antacid, Calcium Carbonate 1000 mg, 72 CHEWABLE TABLETS, DISTRIBUTED

MediumPublished Jun 10, 2026· AI-analyzed Jun 15, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Guardian Drug Co. Inc. has initiated a Class II recall for HyVee Ultra Strength Antacid (Calcium Carbonate 1000 mg) due to the presence of foreign substances, specifically small metallic particles, in the chewable tablets.

Who it affects

This recall affects Guardian Drug Co. Inc. as the manufacturer, Hy-Vee Inc. as the distributor, and pharmaceutical quality and manufacturing professionals involved in solid oral dosage form production.

Why it matters

The presence of metallic particles in an oral tablet suggests a potential failure in the manufacturing or equipment maintenance process, such as equipment wear or inadequate screening. A Class II designation indicates that exposure may cause temporary or medically reversible adverse health consequences, necessitating a thorough investigation into the source of the contamination and a review of batch release procedures.

Practical takeaway

Quality teams should review metal detection protocols and foreign object prevention controls within the tableting and packaging lines. Regulatory and distribution teams must ensure all units associated with the affected UPC are accounted for and that the ongoing recall status is tracked to completion.

FDA source material

Class II. Reason: Presence of foreign substance: small metallic particles in chewable tablets.. Product: HyVee, Ultra Strength Antacid, Calcium Carbonate 1000 mg, 72 CHEWABLE TABLETS, DISTRIBUTED BY: HY-VEE INC., Inc., WEST DES MOINES, IA 50266, UPC: 0 75450 82514 5.. Firm: Guardian Drug Co. Inc. (Dayton NJ United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.